Canada markets open in 5 hours 18 minutes

Stereotaxis, Inc. (STXS)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
2.5600+0.0600 (+2.40%)
At close: 04:00PM EDT
2.6000 +0.04 (+1.56%)
After hours: 06:23PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.5000
Open2.5300
Bid0.0000 x 1000
Ask0.0000 x 1100
Day's Range2.5300 - 2.6650
52 Week Range1.3300 - 3.2900
Volume235,404
Avg. Volume309,156
Market Cap210.25M
Beta (5Y Monthly)1.34
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024

    ST. LOUIS, April 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 first quarter on Monday, May 13, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments. What: Stereotaxis first quarter 2024 fin

  • GlobeNewswire

    Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States

    ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that regulatory submissions were made recently in both Europe and the United States for the MAGiC™ catheter. These submissions follow successful initial clinical results in an ongoing trial. Stereotaxis’ MAGiC catheter is a robotically navigated magnetic ablation catheter designed to perform minimally invasive c

  • GlobeNewswire

    Stereotaxis Reports 2023 Full Year Financial Results

    ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2023. “We enter 2024 having made significant progress in realizing our strategic transformation. This is the year in which we expect all the key puzzle pieces to come together, setting us up for breakout growth to follow,” said David Fische